Deltagen subscribes to new model

With its new deal with Eli Lilly and Co., Deltagen Inc. has launched its migration from gene function specialist into downstream product development.

While DGEN has developed a database of gene function information that is creating revenues on a subscription basis, it also is using its abilities to perform in vivo gene function validation as leverage to obtain needed targets and services...